XNCR - Xencor, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Xencor, Inc.

111 West Lemon Avenue
2nd Floor
Monrovia, CA 91016
United States
626-305-5900
http://www.xencor.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees156

Key Executives

NameTitlePayExercisedYear Born
Dr. Bassil I. Dahiyat Ph.D.Co-Founder, CEO, Pres & Director1.05M1.8M1970
Mr. John J. KuchSr. VP of Fin., CFO & Sec.593.88k1.34M1959
Dr. John R. DesjarlaisSr. VP of Research & Chief Scientific Officer689.66k1.24M1964
Dr. Paul A. FosterSr. VP & Chief Medical Officer702.19k2.81M1954
Mr. Charles LilesAssociate Director and Head of Corp. Communications & Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for the treatment of asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug that is in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG50, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, XmAb23104, and XmAb24306 which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.

Corporate Governance

Xencor, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.